Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
MWN-AI** Summary
Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotech firm based in Vancouver, has reported significant progress in its ongoing Phase I/IIa clinical trial of CMND-100, a non-hallucinogenic treatment for Alcohol Use Disorder (AUD). This trial is being conducted at prestigious institutions including Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. The latest update, released on March 19, 2026, confirms that participants in the third cohort are continuing their treatment regimen successfully, with no serious adverse events reported, underscoring the safety and tolerability of CMND-100.
This trial is crucial as it aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients suffering from moderate to severe AUD. Dr. Adi Zuloff-Shani, the CEO of Clearmind, expressed optimism regarding the successful continuation of the trial, noting the encouraging momentum in both recruitment and outcomes from previous cohorts.
Clearmind’s main focus is on creating revolutionary non-hallucinogenic neuroplastogen-derived therapeutics, addressing major health issues such as AUD. Their innovative approach seeks to combine psychiatric medicine with psychedelic research, positioning themselves in a niche within the biotech industry. The company boasts a robust intellectual property portfolio comprising 19 patent families with 31 granted patents, and plans are in place to expand this further.
As Clearmind continues its clinical advancements, investors and stakeholders remain attentive, recognizing the potential of CMND-100 to serve as a breakthrough treatment for alcohol dependency. The company's stock is actively traded on Nasdaq under the symbol "CMND," signaling growing interest in its pioneering research and therapeutic developments.
MWN-AI** Analysis
Clearmind Medicine Inc. (Nasdaq: CMND) is generating significant excitement with its ongoing Phase I/IIa clinical trial of CMND-100 as a treatment for Alcohol Use Disorder (AUD). Recent updates indicate successful ongoing treatment of participants across esteemed U.S. medical institutions, including Yale University and Johns Hopkins University, reinforcing the company’s strong momentum in clinical research. With no serious adverse events reported so far, the safety and tolerability of CMND-100 continue to build investor confidence.
From a market perspective, this positive trial progress is crucial for Clearmind, which operates in a burgeoning sector that targets pressing health concerns with innovative therapeutics. The company’s strategic focus on developing non-hallucinogenic, neuroplastogen-derived drugs positions it uniquely in the market. Given the expanding acceptance and legalization of psychedelic treatments, Clearmind’s potential success may align well with evolving healthcare trends.
For investors, this presents an intriguing opportunity. However, it’s essential to remain cognizant of the inherent risks in clinical-stage biotech investments, especially as the company navigates later phases of trials and seeks regulatory approvals. Future market performance will rely on trial outcomes and subsequent investor sentiment, particularly if the company secures significant partnerships or funding.
With shares trading on Nasdaq, those interested might consider monitoring the stock as additional data emerges from ongoing trials. Awaiting topline results can provide pivotal insights that could influence stock volatility. Investors should also explore the broader market for comparable biotech firms to gauge how CMND stands amid industry trends.
In summary, while Clearmind represents a potential growth opportunity in an evolving field, prudent investors should maintain a balanced view of potential rewards against the risks typical of the biotech sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful continuation of treatment of participants in the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).
This positive progress follows the Company’s recent announcement on March 11, 2026, regarding the advancement of participant enrollment for the third cohort at Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. Patients at the prestigious U.S. institutions – Yale University and Johns Hopkins University – continue to progress successfully through their treatment protocol, demonstrating continued safety and tolerability with no serious adverse events reported to date.
The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The successful ongoing treatment at these leading U.S. medical centers reflects strong momentum and confidence in CMND-100 as a potential breakthrough therapy for AUD.
“Building on the encouraging recruitment momentum and positive topline results from prior cohorts, we are pleased with the successful continuation of treatment in our U.S. clinical sites,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ**
How does the clinical progress of Clearmind Medicine Inc. (CMND) at prestigious institutions impact investor confidence in the potential success of its non-hallucinogenic treatments for Alcohol Use Disorder (AUD) by March 2026?
What are the expected market implications for Clearmind Medicine Inc. (CMND) following the continued safety and tolerability of its CMND-100 treatment as highlighted in the recent updates from clinical trials?
How might the advancements of Clearmind Medicine Inc. (CMND) in drug development influence the biotech landscape in Canada, particularly regarding investment opportunities in neuroplastogen-derived therapeutics?
What strategies is Clearmind Medicine Inc. (CMND) employing to protect its intellectual property portfolio, and how might this impact its growth trajectory in the biotech sector by March 2026?
**MWN-AI FAQ is based on asking OpenAI questions about Clearmind Medicine Inc. (NASDAQ: CMND).
NASDAQ: CMND
CMND Trading
41.04% G/L:
$3.53 Last:
41,970,858 Volume:
$3.49 Open:
